Kyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancer - KYNB News | RalliesKyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancer
K
KYNB• Investor presentation highlights Phase 2 prostate cancer program and roxadustat plans
- Kyntra Bio highlighted Phase 2 enrollment for FG-3246 monotherapy in metastatic castration-resistant prostate cancer, paired with FG-3180 PET imaging.
- Interim Phase 2 analysis targeted for 4Q 2026, aimed at selecting an optimal Phase 3 dose based on efficacy, safety, pharmacokinetics.
- Roxadustat positioned as a Phase 3-ready U.S. program for anemia in lower-risk MDS with high transfusion burden, following FDA trial-design alignment.
- Phase 3 initiation for roxadustat targeted for 4Q 2026; costs for an internally run study excluded from cash runway projections.
- Cash runway projected into 2028; roxadustat has Orphan Drug Designation in MDS granted in December 2025.
